Indiana unveils draft of A-F school grades model valuing tests and student skills
The Indiana Department of Education (IDOE) released its first draft of its new grading model for schools that, for the first time in the state's history, takes into account not just test scores, but also a student's unique educational experience.
The department was tasked with creating a new A-F school grading model after lawmakers passed House Bill 1498 this legislative session.
Now, the state must create a new methodology for grading how schools perform and hand out letter grades for each campus by the end of 2026.
On June 4, 2025, state leaders presented the first draft of the grading model to the Indiana State Board of Education and Indiana Secretary of Education Katie Jenner says it elevates academic mastery and skill development to be successful after high school.
'While the specifics will iterate along the way, our primary goal will remain the same: to ensure that our future accountability model values all of the key characteristics essential to student success, as well as every student's unique pathway,' Jenner said in a statement.
The board must approve the grading criteria by the end of 2025, but it will have a series of public hearings and likely publish a second draft before the model reaches its final vote.
This first draft of the grading model was made with the foundation of considering the five characteristics already used in the state's 'Graduates Prepared to Succeed' platform, which gathers data points to evaluate schools on:
To evaluate academic mastery, the state will look at standardized test scores from ILEARN, IREAD and the SAT.
To grade career and postsecondary readiness, they will see how many diploma seals are earned.
To grade work ethic, the state will look at attendance rates.
Evaluating the civic, financial and digital literacy will come from the required coursework mandatory for all students in those fields.
Grading the communication and collaboration characteristics is being formulated.
This draft of how schools will be graded looks at specific points in a student's K-12 journey, with an emphasis on grades 3-8, 10th grade and 12th grade.
The letter grades for schools in this first draft are based on the 0-100 scale with an 'F' grade meaning schools only got 0-59 points, a 'D' grade 60-69 points, a 'C' grade 70-79 points, a 'B' grade 80-89 points and an 'A' grade is 90-100 points.
At the elementary level, schools will be graded on how well students perform on ELA and math standardized testing, as well as reading proficiency, specifically among third graders. Attendance will also be a factor in how schools are graded.
Schools teaching students in grades 4-6 will be graded on how well students perform on math, science and social studies tests, as well as whether students are progressing academically compared to the prior year.
More background on this move: Indiana schools will again receive A-F grades, but how they will be measured undecided
High schools will be judged, in part, on students' SAT performance, graduation rates, work-based learning, and certain credentials or college-level credits earned.
The draft also includes a possibility of grading schools on how many English language learning students meet their language proficiency goals that year.
While the formal 30-day public feedback window isn't technically open yet, parents can submit feedback to the IDOE on this first draft starting now.
Anyone who wishes to submit feedback can do so through an online Jotform.
Once the 30-day public comment period opens later this summer, the IDOE will also hold a public hearing where anyone can provide comments in person.
A second draft is expected to be shared late summer or early fall, in which another 30-day window of public comment will happen.
Keep up with school news: Sign up for Study Hall, IndyStar's free weekly education newsletter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 days ago
- Business Wire
Satellos Bioscience Shareholders Elect Two New Board Members
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. 'I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,' said Frank Gleeson, Satellos co-founder and CEO. 'We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.' A highly accomplished biotech and pharmaceutical executive, Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB's worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies, including Cimzia, Briviact, Evenity, Rystiggo, Zilbrysq, and Bimzelx. Her leadership was instrumental in advancing both common and rare disease treatments, with a deep and sustained commitment to improving outcomes for underserved patient populations. Prior to UCB, Loew-Friedrich held senior R&D roles at Schwarz Pharma, BASF Pharma, and Hoechst/Aventis, where she contributed to the development and success of market-leading drugs such as Humira, Arava, Actonel, Vimpat, and Neupro. Dr. Ho is a seasoned pharmaceutical and biotech executive with broad leadership experience across commercial strategy, business development, financing, and board governance. He has held senior roles at global companies including Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, with expertise spanning ophthalmology, immunology, oncology, and dermatology. As CEO of Medigene AG, he led a strategic transformation and established and extended key partnerships with BioNTech, Regeneron, WuXi Biologics and EpimAb Biotherapeutics. Previously, as EVP & chief business officer at Connect Biopharma, he was instrumental in raising over $350 million through IPO and private funding. He also serves on the boards of Antennova Inc. and Peptomyc S.L., and as executive-in-residence at New Rhein Healthcare Investors. As part of the Annual General Meeting, Rima Al-awar, Ph.D., William Jarosz, J.D., and William McVicar, Ph.D., did not stand for reelection. 'I want to personally thank Rima, Bill and Bill for their dedicated service, thoughtful leadership and support,' said Gleeson. 'Their guidance helped position Satellos for continued progress, and we wish them all the best in their future endeavors.' About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. 530509798v.1
New York Post
16-06-2025
- New York Post
Caitlyn Jenner flees Israel after being forced to hide in bomb shelter in face of Iran attacks
Caitlyn Jenner has fled Israel after Iran's ongoing missile attacks forced her to hide in a bomb shelter. The 75-year-old Olympic gold medalist flew to Tel Aviv last Thursday to be the guest of honor at a Pride parade the next day, which was then canceled because of the air attacks — and was pictured drinking a glass of wine in a bunker as missiles landed overhead. 'I am happy to stand with Israel today, now more than ever,' she wrote Friday, sharing the photo of missiles streaking over the Israeli city. 'Pray for us all. We will prevail.' 7 Caitlyn Jenner at the Western Wall in Jerusalem. Arnon Bossani via State of Israel 7 Caitlyn Jenner and Tel Aviv Mayor Ron Huldai on June 11th. X/@MayorOfTelAviv 7 An explosion erupts from a missile fired from Iran in Tel Aviv, Israel. ATEF SAFADI/EPA-EFE/Shutterstock 'I am a friend, advocate, ally, and thank you to the Israeli people for making me family,' she wrote Saturday, while also praising Israeli Prime Minister Benjamin Netanyahu for the preemptive attack on Iran's nuclear experts and facilities. 'The leadership by Bibi, and Israel's closest ally President Donald Trump will not allow this reckless violence towards so many [to] continue. Israeli jets overhead in Iran now,' Jenner wrote. '(Bye bye terrorists). We will liberate Iran's citizens.' 7 Caitlyn Jenner landing at the airport in Israel in a video posted to instagram in June. Instagram/@caitlynjenner Jenner eventually crossed by land into neighboring Jordan on Sunday after flights out of Israel were canceled, the Times of Israel reported. She was then due to fly back home to Los Angeles from Jordan. The Pride parade, the largest in the Middle East, was canceled because of the ongoing bombardments. 7 Caitlyn Jenner attends a press conference, prior to her attendance at the Tel Aviv Pride Parade on June 13. REUTERS 7 Caitlyn Jenner praying at the Western Wall. Arnon Bossani via State of Israel Jenner had earlier in her trip visited the site of some of the Oct. 7, 2023 terror attacks by Hamas, meeting survivors as well as relatives of hostages. When the air assaults started, Jenner took to a shelter — where influencer Regev Gur shared a photo of her smiling and drinking a glass of red wine. 'What did you do during the alerts, because I'm drinking wine with Caitlyn,' Gur wrote. 7 Caitlyn Jenner and influencer Regev Gur drinking wine in a bomb shelter, as the air assaults began. In an earlier post, Regev joked that he had earlier been joking to Jenner that Israel is 'safer than Los Angeles,' after Jenner's home city was hit by days of violence following anti-ICE protests. So far, Iranian airstrikes have killed at least 24 Israelis since Friday, including two children.
Business Wire
16-06-2025
- Business Wire
Satellos Bioscience to Participate in PPMD's Annual Conference in Las Vegas
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families' experiences, and share updates on its science and mission to regenerate muscle from within. 'We're looking forward to connecting in person with families and advocates who are at the heart of this work,' said Frank Gleeson, Co-founder and CEO of Satellos. 'This conference is a powerful reminder of why we're focused on developing a new approach to treat Duchenne — one that aims to restore the body's ability to repair muscle.' Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company's booth in the exhibition hall. About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
